CDG (2-Deoxy-2-(2-oxo-2H-chromen-7-yl)Amino-D-Glucose)

Product Description

CDG (2-Deoxy-2-(2-oxo-2H-chromen-7-yl)Amino-D-Glucose)
Catalog number: MDP0883
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.5 mg
Molecular Weight or Concentration: 323.3 g/mol
Supplied as: Powder
Applications: molecular probe in the monitoring of cellular glucose uptake
Storage: -20°C
Keywords: 2-Deoxy-2-(2-oxo-2H-chromen-7-yl)Amino-D-Glucose
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.
Indication for Use:This product is for Research Use Only. This product is NOT for human or animal use.

References:
1: Lam C, Krasnewich DM. PMM2-CDG. 2005 Aug 15 [updated 2021 May 20]. In: Adam
MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors.
GeneReviews^® [Internet]. Seattle (WA): University of Washington,
Seattle; 1993–2021.

2: Radenkovic S, Bird MJ, Emmerzaal TL, Wong SY, Felgueira C, Stiers KM, Sabbagh
L, Himmelreich N, Poschet G, Windmolders P, Verheijen J, Witters P, Altassan R,
Honzik T, Eminoglu TF, James PM, Edmondson AC, Hertecant J, Kozicz T, Thiel C,
Vermeersch P, Cassiman D, Beamer L, Morava E, Ghesquière B. The Metabolic Map
into the Pathomechanism and Treatment of PGM1-CDG. Am J Hum Genet. 2019 May
2;104(5):835-846.

3: Monticelli M, Liguori L, Allocca M, Andreotti G, Cubellis MV.
β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In
Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for
the Most Common Disorder of Glycosylation, PMM2-CDG. Int J Mol Sci. 2019 Aug
26;20(17):4164.

4: Schrapers E, Tegtmeyer LC, Simic-Schleicher G, Debus V, Reunert J, Balbach S,
Klingel K, Du Chesne I, Seelhöfer A, Fobker M, Marquardt T, Rust S. News on
Clinical Details and Treatment in PGM1-CDG. JIMD Rep. 2016;26:77-84.

5: Morava E. Galactose supplementation in phosphoglucomutase-1 deficiency;
review and outlook for a novel treatable CDG. Mol Genet Metab. 2014
Aug;112(4):275-9.

6: Marquardt T, Bzduch V, Hogrebe M, Rust S, Reunert J, Grüneberg M, Park J,
Callewaert N, Lachmann R, Wada Y, Engel T. SLC37A4-CDG: Mislocalization of the
glucose-6-phosphate transporter to the Golgi causes a new congenital disorder of
glycosylation. Mol Genet Metab Rep. 2020 Aug 21;25:100636.

7: Gao N, Shang J, Lehrman MA. Analysis of glycosylation in CDG-Ia fibroblasts
by fluorophore-assisted carbohydrate electrophoresis: implications for
extracellular glucose and intracellular mannose 6-phosphate. J Biol Chem. 2005
May 6;280(18):17901-9.

8: He MF, Fu HQ, Su BF, Yang HQ, Tang JQ, Hu CW. Theoretical insight into the
coordination of cyclic β-D-glucose to [Al(OH)(aq)](2+) and [Al(OH)2(aq)](1+)
ions. J Phys Chem B. 2014 Dec 4;118(48):13890-902.

9: Radenkovic S, Witters P, Morava E. Central nervous involvement is common in
PGM1-CDG. Mol Genet Metab. 2018 Nov;125(3):200-204.
10: Iyer S, Sam FS, DiPrimio N, Preston G, Verheijen J, Murthy K, Parton Z,
Tsang H, Lao J, Morava E, Perlstein EO. Repurposing the aldose reductase
inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of
glycosylation PMM2-CDG. Dis Model Mech. 2019 Nov 11;12(11):dmm040584.

Products Related to CDG (2-Deoxy-2-(2-oxo-2H-chromen-7-yl)Amino-D-Glucose) : Carbohydrates